These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 18648187)
1. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187 [TBL] [Abstract][Full Text] [Related]
2. [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer]. Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC Ai Zheng; 2006 Aug; 25(8):1035-8. PubMed ID: 16965689 [TBL] [Abstract][Full Text] [Related]
3. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146 [TBL] [Abstract][Full Text] [Related]
5. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598 [TBL] [Abstract][Full Text] [Related]
6. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326 [TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039 [No Abstract] [Full Text] [Related]
8. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926 [TBL] [Abstract][Full Text] [Related]
9. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
11. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC). Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. McWilliams RR; Goetz MP; Morlan BW; Salim M; Rowland KM; Krook JE; Ames MM; Erlichman C Clin Colorectal Cancer; 2007 May; 6(7):516-21. PubMed ID: 17553200 [TBL] [Abstract][Full Text] [Related]
13. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243 [TBL] [Abstract][Full Text] [Related]
14. [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer]. Ishibashi K; Okada N; Ishiguro T; Okita T; Mitsuhashi T; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H Gan To Kagaku Ryoho; 2008 Nov; 35(12):2289-91. PubMed ID: 19106599 [TBL] [Abstract][Full Text] [Related]
15. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748 [TBL] [Abstract][Full Text] [Related]
17. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer. Fisher MD Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365 [No Abstract] [Full Text] [Related]
18. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Moreau LC; Rajan R; Thirlwell MP; Alcindor T Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831 [TBL] [Abstract][Full Text] [Related]
19. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Lévi F; Misset JL; Brienza S; Adam R; Metzger G; Itzakhi M; Caussanel JP; Kunstlinger F; Lecouturier S; Descorps-Declère A Cancer; 1992 Feb; 69(4):893-900. PubMed ID: 1735081 [TBL] [Abstract][Full Text] [Related]
20. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]